Background. Some anaesthetic agents exhibit an age-dependent analgesic effect, for example nitrous oxide, which is ineffective in newborn rats. We investigated whether a similar time dependency existed for the responses to the volatile anaesthetic isoflurane.
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The assumption that analgesic agents used in the adult population will be equally efficacious in the paediatric population has recently been challenged. 5 We found that nitrous oxide was an ineffective antinociceptive agent in young Fischer rats. The mechanism may relate to differences in pain processing systems between mature and immature animals; notably, neonates lack functional descending inhibitory neurons (DIN) 6 7 connecting spinal and supraspinal sites. Nitrous oxide requires functional DIN to exert antinociceptive actions and thus is ineffective in the neonate. 5 Therefore, the use of analgesic agents, which require functional DIN to be effective in the young may be contraindicated.
Isoflurane is known to mediate nociception through both DIN-dependent and DIN-independent mechanisms. 8 In addition, isoflurane is known to modulate nociceptive pathways in a complex manner via both pronociceptive and antinociceptive actions. However, at the level of the spinal cord isoflurane is thought to exert an antinociceptive effect. 8 We have shown previously antinociceptive efficacy using an in vitro paradigm of the neonatal rat spinal cord, 9 suggesting that isoflurane may be effective in vivo when functional DIN are absent (e.g. the neonate). Furthermore, in a model of spinal cord transection, where DIN are rendered non-functional, isoflurane inhibited wide dynamic neuron sensory transmission. 10 We therefore sought to clarify the antinociceptive action of isoflurane in vivo at various ages in the formalin test using both behavioural and immunohistochemical markers of nociception.
Isoflurane is a potent hypnotic agent in both the adult and neonate; however, the neonate is relatively resistant to the anaesthetic effects of volatile anaesthetic agents assessed by MAC, an operational descriptor. 11 12 We assessed the hypnotic effects of this agent at four age groups in order to quantify the confounding effects on the behavioural response to nociceptive stimuli and to examine the age dependency of isoflurane induced hypnosis.
Methods

General procedures and animals
The study protocol was approved by the Home Office (UK). Fischer rats used for the entire study (B&K Universal, Grimston Aldbrough Hull, UK) were provided ad libitum with food and water, and artificial lighting between 06.00 and 18.00. The date of birth for the animals was defined as 0-day-old. Experiments were performed on rat pups of 7, 16, and 28 days old and on adult rats (11-12 weeks old), which are equivalent to neonate, toddler, adolescent, and adult. 13 
Nociception experiments
Three cohorts were used at each age group: saline group, oxygen 100% with saline intraplantar injection (i.p.i); formalin group, oxygen 100% with formalin i.p.i.; isoflurane+ formalin group, isoflurane 0.5% in oxygen and formalin i.p.i. The gases were delivered at a flow rate of 2 litre min À1 . The concentration of isoflurane was measured using infrared gas spectroscopy (Model 5250 RGM, Ohmeda). Twenty minutes after oxygen or isoflurane administration, formalin 5% (or saline) was injected subcutaneously into the plantar surface of the animal's left hind paw. The volumes of formalin or saline injected were adjusted for each age group as reported previously 5 and were as follows: 10 ml for 7 days old; 15 ml for 16 days old; 20 ml for 28 days old; 50 ml for adults.
Nociceptive intensity scoring
Immediately after injection of formalin, behaviour was recorded for 60 min with a video camera (MegaPixel, Digital Handycam, Sony) positioned approximately 50 cm beneath the floor of the chamber to allow an unobstructed view of the paws (visible via a video monitor) and to facilitate recording of animal behaviour. The chamber and holding area for pups waiting to be tested were maintained at room temperature throughout the experiment.
Nociceptive behaviour was assessed in the 7-day-old pups (n=3-4) for the presence ('1') or absence ('0') of flexion, shaking, and whole body jerking per epoch of time 14 and calculated as nociceptive score=T/300, where T is the duration (s) of nociceptive behaviour exhibited during consecutive 300 s post-injection epochs.
Sixteen-day-old rats and older were scored across four categories of pain behaviour (n=3-4 per age group): no pain (the injected paw was in continuous contact with floor='0'), favouring (the injected paw rested lightly on the floor='1'), lifting (the injected paw was elevated all the time='2') and licking (licking, biting or shaking of the injected paw='3') 14 and calculated as nociceptive score=(T1+[T2·2]+[T3·3])/ 300, where T1, T2, and T3 are the durations (s) spent in categories 1, 2, or 3 per 300 s epoch.
Loss of righting reflex
At each age we investigated the sedative effect of isoflurane using the loss of righting reflex (LORR) endpoint defined as the inability of animals to right themselves when positioned in a supine position. The percentage of animals with LORR at concentrations of isoflurane 0.1% and above (using increments of 0.1%) was used to establish dose-response curves (n=8-10). After adjusting the vaporizer to achieve a new concentration, a 35-min equilibration period was allowed to elapse before testing.
Immunohistochemical staining and quantitative counting of c-Fos
Ninety minutes after the formalin injection, animals were deeply anesthetized with pentobarbital (100 mg kg À1 , i.p.) and perfused with paraformaldehyde 4% (n=4 per age group). The whole spinal cord was removed. The lumbar enlargement was sectioned transversely at 30 mm and was then stained for c-Fos as described previously. 5 Briefly, sections were incubated for 30 min in H 2 O 2 0.3% in methanol and thereafter washed three times in 0.1 M phosphate-buffered saline (PBS). Following this, the sections were incubated for 1 h in a 'blocking solution' consisting of donkey serum 3% and Triton-X 3% in PBS (PBT) and subsequently incubated overnight at 4 C in 1:5000 goat anti-c-Fos antibody (sc-52-G, Santa Cruz Biotechnology, Santa Cruz, CA) in PBT with donkey serum 1%. The sections were then rinsed three times with PBT and incubated with 1:200 donkey anti-goat IgG (Vector laboratories, Burlingame, CA) in PBT with donkey serum 1% for 1 h. The sections were washed again with PBT and incubated with avidin-biotin-peroxidase complex (Vector Laboratories) in PBT for 1 h. The sections were rinsed three times with PBS and stained with 3,3 0 -diaminobenzidine (DAB) with nickel ammonium sulphate to which hydrogen peroxide was added (DAB kit, Vector Laboratories). When the staining was complete, the sections were rinsed in PBS followed by distilled water and mounted, dehydrated with ethanol 100%, cleaned with 100% xylene and covered with cover slips.
Photomicrographs of three sections per animal were scored ipsilaterally for c-Fos-positive neurons by an observer who was blinded to the experimental treatment. Sections expressing maximal levels of c-Fos were selected for scoring. For the purpose of localizing the c-Fos-positive cells to functional regions of the spinal cord, each section was divided into A/B (laminae I-II or the superficial area), C (laminae II-IV or nucleus proprius area), D (laminae V-VI or the neck area, and E (laminae VII-X or the ventral area). 15 
Data analysis
Nociceptive intensity scoring against time in each animal was plotted and the area under curve (over a 60 min time period) (AUC) from each animal was calculated. Mean c-Fos-positive neurons for three representative sections in each region, as described above, was the aggregate score for each animal. The results of nociceptive intensity or c-Fos-positive neurons are reported as means (SEM). Statistical analysis was performed by one-way analysis of variance, followed by Newman-Keuls test. A P value <0.05 was regarded as statistically significant.
LORR concentration response data were fitted according to the method of Waud 16 to a logistic equation of the form:
where P is the percentage of the population anaesthetized, C is the drug concentration, n is the slope parameter, and ED 50 is the drug dose for half a maximal effect.
Results
Behavioural nociceptive response
Time course of the nociceptive response of each cohort in each age category is presented in Figure 1 . Isoflurane significantly decreased the AUC relative to oxygen after formalin i.p.i. (Table 1) . During the pre-injection period, all animals were awake and active. Following injection with formalin in the presence of oxygen 100%, the 7-day-old animals exhibited intense nociceptive behaviour. Administration of isoflurane at 0.5% attenuated this nociceptive response.
Similarly formalin i.p.i. in the 16-day-old, 28-day-old, and adult groups led to intense nociceptive behaviour. For each cohort there was a significant decrease in nociceptive behaviour with administration of isoflurane at 0.5%.
Immunohistochemical nociceptive response
Formalin-induced c-Fos expression at the lumbar level of the spinal cord ipsilateral to the site of injection increased at all age groups in the outer laminae of the dorsal horn (laminae I-II or A/B) (Fig. 2) . Exposure to isoflurane at 0.5% significantly suppressed c-Fos expression in this region at all ages indicating suppression of nociception (Fig. 3) . Isoflurane administration reduced c-Fos expression in lamina A/B (I-II) in response to formalin by 60% (P<0.001) in 7-day-old rats, 40% (P<0.05) in 16-day-old rats, 74% (P<0.001) in 28 day-old-rats, and 34% (P<0.05) in adults rats (Fig. 3) .
LORR
Isoflurane produced a dose-dependent sedative effect with the neonate showing marked hypnotic sensitivity (Fig. 4) .
The LORR ED 50 for 7-day-old rats was 0.25%, which is significantly less than 16-day-old (0.54%), 28-day-old (0.56%), and adult (0.65%) rats (P<0.01). Adult rats were less sensitive to the sedative effects of isoflurane than 7-day-old (P<0.01) and 16-and 28-day-old rats (P<0.05).
Discussion
Isoflurane at 0.5% possesses antinociceptive efficacy at all developmental stages tested in Fischer rats. Extrapolation of these findings suggests that isoflurane 0.5% may be analgesic in humans from neonatal ages onwards. 13 In contrast to neonatal resistance to isoflurane anaesthesia as measured by MAC, 11 12 isoflurane is a potent hypnotic in the very young. This information not only dissociates MAC and hypnosis in the very young, but highlights the complex interaction between analgesia, immobility, and hypnosis that contributes to MAC assessment. Furthermore, increasing age appears to correlate with increasing resistance to the hypnotic effects of isoflurane as assessed by loss of righting reflex. As the hypnotic effect of isoflurane may confound the behavioural assessment of nociception, we complimented behavioural assessment with immunohistochemical c-Fos assays of antinociceptive efficacy. However, there are still some limitations using c-Fos for this kind of study although it could be considered as a classic marker of pain circuitry. In terms of the anatomical pattern of c-Fos expression in the spinal cord following noxious stimuli, there is a difference between immature and adult rats where it is located more in superficial dorsal region of the spinal cord in fetus but in all laminae of the dorsal horn in adults 15 17 and this was confirmed by the present study (Figs 2 and 3 ). It has also been suggested that the sensitivity of c-Fos expression following noxious stimuli in rats is age and stimulus-intensity dependent. 15 Another limitation is that it would have been ideal to include a isoflurane+saline group for better comparison. However, this has no implications for the antinociceptive efficacy of isoflurane and hence this group was omitted originally in the experimental protocol. Nevertheless, these limitations would not affect our conclusion, as we did not compare the antinociceptive efficacy of isoflurane directly between age groups. The comparisons were made with aged-matched controls only.
The data are qualitatively different from those that we reported recently with nitrous oxide 5 in which no antinociceptive effect (neither behaviourally nor immunohistochemically) was noted in animals younger than 23 days old. In contrast, we have found xenon to be effective at all ages in this paradigm, 18 possibly because of the fact that xenon acts at the level of the spinal cord. 19 Isoflurane is known to possess direct action at the level of the spinal cord [8] [9] [10] and this is reflected in vivo in 7-day-old rats where DIN are not functional, yet c-Fos expression, stimulated by formalin, is attenuated. The mechanism whereby isoflurane Isoflurane, antinociceptive and hypnotic effect and age exerts this effect at the level of the spinal cord is currently unknown; however, it is possible that there is a common mechanism transcending the respective age groups. For example, while isoflurane is known to interact with cholinergic receptors 20 mediating hyperalgesic responses at low doses, 21 this mechanism is not thought to contribute to isoflurane's action in the spinal cord. 22 The hyperalgesic effects of isoflurane are especially relevant to this work as doseresponse curves are yet to be established in neonates and therefore while we know that isoflurane 0.5% is an effective antinociceptive dose we have no information about the potential for hyperalgesic/analgesic effects at other doses. Dose-ranging studies are required to fully investigate the effect of isoflurane in the neonate.
Isoflurane potentiates both glycinergic and GABAergic systems in vitro 23 24 and in vivo 25 26 and may modulate nociception at a spinal level through these pathways. Recently co-synapses containing both glycinergic and GABAergic neurotransmission have been detected in the dorsal horn of the neonatal spinal cord but not in the adult spinal cord, indicating a developmental shift in inhibitory neurotransmission. 27 These co-synapses may provide a more potent intrinsic inhibitory circuit at the spinal cord level in the neonate and may be a compensatory mechanism for a lack of contribution to antinociception by DIN. Indeed, during development these co-synapses disappear at a time, which approximates to the onset of functional DIN. 27 Isoflurane by potentiating these neonatal inhibitory circuits may augment the neonate's intrinsic antinociceptive system.
The apparent dissociation between hypnosis and MAC is of great interest. Investigation of this by quantification the MAC fraction of the anaesthetic in neonates would provide useful information. A rough estimation of MAC-fraction as the ratio of MAC:hypnosis (ED 50 ) in the rat (comparing our 7-day-old data against the 9-day-old MAC data 12 ) for the neonate, is 2.34:0.25 while the adult it is 1.12:0.65 (comparison of our adult rat data against that of Orliaguet and collegues 12 ). This indicates that the neonate is more susceptible to the hypnotic effects of isoflurane than the adult and while we have started to describe mechanistic features of these effects in the adult 28 we are yet to elucidate mechanisms of hypnosis in the very young. Furthermore, it is also possible that other aspects of the anaesthetic state are less sensitive in the neonate such as immobility and pain processing mechanisms. This interesting facet of anaesthestic agents deserves further exploration.
Anaesthesia in the neonate has recently been associated with long-term detrimental side effects. 29 Whether this is a correlate of anaesthesia, individual anaesthetic agents or a combination of anaesthetic agents is currently unknown. However, isoflurane at 0.75% and above induced neurodegeneration in rats when administered alone 29 and therefore isoflurane should not be regarded as entirely safe in the neonate if the results of this animal study can be extrapolated to humans. It is clear that the provision of satisfactory analgesia and anaesthesia must be balanced against the potential to cause harm, and thus a well-defined anaesthetic profile of an agent at each age must be established.
In summary, isoflurane at 0.5% is an effective antinociceptive agent at developmental stages equivalent to the human neonate and older. Thus unlike nitrous oxide, which has no antinociceptive effect in this model, 5 isoflurane is a potent antinociceptive agent. In addition, isoflurane is a potent hypnotic agent at each age tested. However the neonate, while insensitive to isoflurane anaesthesia as assessed by MAC, is extremely sensitive to the hypnotic effect of isoflurane. Further investigation of the MAC-fraction of isoflurane in the newborn is warranted. Log dose-response curves of the hypnotic effect of isoflurane 0.5% at different ages in Fischer rats (n=8-10). LORR (expressed as percentage of animals) was used to define the onset of hypnosis. Seven-day-old rats have significantly lower ED 50 than 16-day-old, 28-day-old, and adult rats (P<0.01). Adult rats have significantly higher ED 50 than younger rats (P<0.05).
